BR9803144A - Dispersões farmacêuticas sólidas com uma biodisponibilidade aumentada. - Google Patents

Dispersões farmacêuticas sólidas com uma biodisponibilidade aumentada.

Info

Publication number
BR9803144A
BR9803144A BR9803144-9A BR9803144A BR9803144A BR 9803144 A BR9803144 A BR 9803144A BR 9803144 A BR9803144 A BR 9803144A BR 9803144 A BR9803144 A BR 9803144A
Authority
BR
Brazil
Prior art keywords
solid pharmaceutical
increased bioavailability
pharmaceutical dispersions
dispersions
biavailability
Prior art date
Application number
BR9803144-9A
Other languages
English (en)
Inventor
Willian John Curatolo
Scott Max Herbig
James Alan Schrive Nightingale
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21996463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9803144(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9803144A publication Critical patent/BR9803144A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J8/00—Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes
    • B01J8/005—Separating solid material from the gas/liquid stream

Abstract

Patente de Invenção: <B>"DISPERSõES FARMACêUTICAS SóLIDAS COM UMA BIODISPONIBILIDADE AUMENTADA"<D>. As dispersões sólidas por pulverização que compreendem uma droga fracamente solúvel e succinato de acetato de hidroxipropil-metilcelulose (HPMCAS) fornecem uma acrescida solubilidade aquosa e/ou biodisponibilidade num ambiente de utilização.
BR9803144-9A 1997-08-11 1998-08-11 Dispersões farmacêuticas sólidas com uma biodisponibilidade aumentada. BR9803144A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5522197P 1997-08-11 1997-08-11

Publications (1)

Publication Number Publication Date
BR9803144A true BR9803144A (pt) 2000-01-11

Family

ID=21996463

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9803144-9A BR9803144A (pt) 1997-08-11 1998-08-11 Dispersões farmacêuticas sólidas com uma biodisponibilidade aumentada.

Country Status (14)

Country Link
US (7) US8263128B2 (pt)
EP (1) EP0901786B1 (pt)
JP (1) JP2984661B2 (pt)
CN (3) CN1981742A (pt)
AT (1) ATE364374T1 (pt)
BR (1) BR9803144A (pt)
CA (1) CA2245269C (pt)
CY (1) CY1107726T1 (pt)
DE (1) DE69837903T2 (pt)
DK (1) DK0901786T3 (pt)
ES (1) ES2287971T3 (pt)
IL (1) IL125627A (pt)
PT (1) PT901786E (pt)
TW (1) TWI230079B (pt)

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
DE60039377D1 (de) * 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
DE60007592T2 (de) * 1999-09-30 2004-09-16 Pfizer Products Inc., Groton Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
HUP0204372A3 (en) 1999-12-23 2004-06-28 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
KR100523127B1 (ko) * 1999-12-23 2005-10-20 화이자 프로덕츠 인코포레이티드 하이드로겔계 약물 투여 형태
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
US20010053778A1 (en) * 2000-03-16 2001-12-20 Hoover Dennis J. Pharmaceutical compositions of glycogen phosphorylase inhibitors
UY26615A1 (es) * 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2002038126A2 (en) * 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
AU1987802A (en) * 2000-11-29 2002-06-11 Lyotropic Therapeutics Llc Solvent systems for pharmaceutical agents
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US6904706B2 (en) * 2001-04-24 2005-06-14 U Turn Sports Co., Llc Mo Llc. Sandal, thong or the like with reversible tongue, vamp, or strap
WO2003000294A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
ATE444060T1 (de) 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
TNSN03137A1 (en) * 2001-06-22 2005-12-23 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
CA2450748A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
NZ529490A (en) * 2001-06-22 2005-08-26 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
KR100758045B1 (ko) 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
CN1688291A (zh) * 2002-02-01 2005-10-26 辉瑞产品公司 含有固体药物分散体的即刻释放剂型
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
ATE395044T1 (de) * 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
RS61604A (en) 2002-02-01 2006-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
WO2003072139A1 (en) * 2002-02-26 2003-09-04 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
JP2006500349A (ja) 2002-08-12 2006-01-05 ファイザー・プロダクツ・インク 半順序薬剤およびポリマーの医薬組成物
WO2004069180A2 (en) 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
JP2004339162A (ja) * 2003-05-16 2004-12-02 Shin Etsu Chem Co Ltd 難溶性薬物を含む医薬用固形製剤とその製造方法
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20070190129A1 (en) * 2003-09-02 2007-08-16 Pfizer Inc. Sustained release dosage forms of ziprasidone
JP2007511500A (ja) * 2003-11-14 2007-05-10 ファイザー・プロダクツ・インク 肥満治療のためのｍｔｐ阻害剤の固体非晶性分散体
AU2004303425C1 (en) * 2003-12-19 2010-02-18 Schering Corporation Pharmaceutical compositions
KR100799802B1 (ko) 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
EA010888B1 (ru) 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Тетраазабензо[е]азуленовые производные и их аналоги
DE602005010074D1 (de) * 2004-05-28 2008-11-13 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
AU2005253957B2 (en) * 2004-06-08 2011-08-25 Janssen Pharmaceutica Nv Pharmaceutical compositions
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
PL1773816T3 (pl) 2004-06-24 2015-06-30 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
EP1789022A2 (en) * 2004-08-31 2007-05-30 Pfizer Products Incorporated Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
EP1789020A2 (en) * 2004-08-31 2007-05-30 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
EP1829549A1 (en) * 2004-12-17 2007-09-05 Ono Pharmaceutical Co., Ltd. Amorphous composition
WO2006069159A2 (en) * 2004-12-20 2006-06-29 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising amorphous benzimidazole compounds
WO2006079921A2 (en) 2005-01-28 2006-08-03 Pfizer Products Inc. Drying of drug-containing particles
GB0502790D0 (en) * 2005-02-10 2005-03-16 Univ London Pharmacy Solid dispersion of hydrophobic bioactive
WO2006112649A1 (en) * 2005-04-20 2006-10-26 Ctc Bio, Inc. Pharmaceutical composition containing sibutramine free base and manufacturing method thereof
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
PT1906926E (pt) * 2005-07-28 2011-01-26 Otsuka Pharma Co Ltd Composição farmacêutica que contém derivados de 2,3-di-hidro-6-nitroimidazo[2,1-b]oxazole
US10532028B2 (en) * 2005-07-28 2020-01-14 Isp Investments Llc Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
AU2006280511A1 (en) * 2005-08-12 2007-02-22 Astrazeneca Ab Process
ES2414434T3 (es) * 2005-08-29 2013-07-19 Sanofi-Aventis U.S. Llc Dispersiones sólidas amorfas de 7-cloro-N,N,5-trimetil-4-oxo-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
BRPI0708957A2 (pt) * 2006-03-20 2011-06-28 Vertex Pharma composições farmacêuticas
WO2007109604A2 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
PL2007756T3 (pl) 2006-04-07 2016-01-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US7772213B2 (en) * 2006-07-27 2010-08-10 Nathan Strick Composition for the treatment of inflammatory conditions
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008092057A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Formulation process method to produce spray dried products
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2185544B1 (en) 2007-07-19 2014-11-26 Cymabay Therapeutics, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders
US20090062538A1 (en) * 2007-09-05 2009-03-05 Surya Narayana Devarakonda Amorphous valganciclovir hydrochloride
JPWO2009038112A1 (ja) * 2007-09-21 2011-01-06 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
US9254268B2 (en) * 2007-09-25 2016-02-09 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
DE102008004893A1 (de) 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009140105A2 (en) 2008-05-14 2009-11-19 Merck & Co., Inc. Formulations for cathepsin k inhibitors
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
ES2552087T3 (es) 2009-02-05 2015-11-25 Tokai Pharmaceuticals, Inc. Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
EP2408750B1 (en) 2009-03-20 2015-08-26 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
MX349923B (es) * 2009-04-03 2017-08-21 Hoffmann La Roche Composiciones del ácido propano-1-sulfónico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil]-amida y el uso de las mismas.
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP5909185B2 (ja) 2009-10-01 2016-04-26 シマベイ セラピューティクス， インコーポレーテッド 置換テトラゾール−１−イルフェノキシメチルチアゾール−２−イルピペリジニルピリミジン塩
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
EP2499140A1 (en) 2009-11-10 2012-09-19 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
KR101478517B1 (ko) 2009-11-10 2015-01-02 화이자 인코포레이티드 Ｎ1-피라졸로스피로케톤 아세틸-ｃｏａ 카복실라아제 억제제
CN109081804B (zh) * 2010-03-25 2021-12-10 弗特克斯药品有限公司 环丙烷甲酰胺的固体形式
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
SG186248A1 (en) 2010-06-09 2013-01-30 Abbvie Inc Solid dispersions containing kinase inhibitors
CN103153343B (zh) * 2010-06-14 2015-02-11 陶氏环球技术有限责任公司 具有提高的醋酸酯和琥珀酸酯取代的醋酸羟丙基甲基纤维素琥珀酸酯
CN103037843A (zh) 2010-06-23 2013-04-10 麦它波莱克斯股份有限公司 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
ES2602111T3 (es) 2010-09-30 2017-02-17 Pfizer Inc Inhibidores de acetil-CoA carboxilasas de N1-pirazoloespirocetona
PL2632925T3 (pl) 2010-10-29 2015-10-30 Pfizer N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
PL2672967T3 (pl) 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2654726A4 (en) * 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd SOLID DISPERSION FORMULATIONS AND METHODS OF USE
CN106117205B (zh) 2011-04-22 2018-09-21 辉瑞大药厂 用作乙酰辅酶a羧化酶抑制剂类的吡唑并螺酮衍生物
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
US9095585B2 (en) 2011-07-21 2015-08-04 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds
WO2013117671A1 (fr) * 2012-02-07 2013-08-15 Centre National De La Recherche Scientifique (C.N.R.S) Préparation de nanoparticules par évaporation flash
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
WO2013150416A1 (en) 2012-04-06 2013-10-10 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2013169523A1 (en) * 2012-05-07 2013-11-14 Bpsi Holdings, Llc. Solubility enhanced compositions
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
EP2874607B1 (en) * 2012-07-17 2017-05-31 Dow Global Technologies LLC Solid dispersion comprising a highly substituted hydroxyalkyl methylcellulose
KR102138544B1 (ko) * 2012-08-24 2020-07-28 다우 글로벌 테크놀로지스 엘엘씨 신규한 하이드록시알킬 메틸 셀룰로즈 아세테이트 석시네이트
EP2888291A1 (en) * 2012-08-24 2015-07-01 Dow Global Technologies LLC Process for preparing an ester of a cellulose ether in the presence of an aliphatic carboxylic acid
MX2015002429A (es) * 2012-08-24 2015-06-22 Dow Global Technologies Llc Eteres de celulosa esterificados novedosos de alto peso molecular y homogeneidad.
WO2014041487A2 (en) * 2012-09-11 2014-03-20 Dr. Reddy's Laboratories Limited Enzalutamide polymorphic forms and its preparation
EP3971167A1 (en) 2012-09-11 2022-03-23 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
CA3053189A1 (en) * 2012-12-20 2014-06-26 Kashiv Biosciences, Llc Orally disintegrating tablet formulation for enhanced bioavailability
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
CN105748499B (zh) 2013-01-31 2018-12-28 吉利德制药有限责任公司 两个抗病毒化合物的联用制剂
US9492550B2 (en) 2013-03-01 2016-11-15 Hercules Llc Pharmaceutical compositions with enhanced performance and improved processability
EP2964203B1 (en) 2013-03-07 2019-04-03 Dow Global Technologies LLC Novel esterified cellulose ethers of very high molecular weight
KR101661952B1 (ko) 2013-03-07 2016-10-04 다우 글로벌 테크놀로지스 엘엘씨 극저점도의 신규한 에스테르화된 셀룰로스 에테르
EP4066841A1 (en) 2013-03-14 2022-10-05 University of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
CN103242542B (zh) * 2013-05-29 2015-04-15 南京农业大学 非晶纤维素分散液的生产方法
EP3033088A4 (en) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
CA2926793C (en) 2013-10-11 2022-11-22 Lawrence S. ZISMAN Spray-dry formulations for treating pulmonary arterial hypertension
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN115708827A (zh) * 2014-01-09 2023-02-24 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合物和方法
WO2015119572A1 (en) 2014-02-04 2015-08-13 National University Of Singapore Method of pulsed laser-based large area graphene synthesis on metallic and crystalline substrates
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
EA036325B1 (ru) 2014-03-14 2020-10-27 Аджиос Фармасьютикалз, Инк. Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
TR201809388T4 (tr) 2014-03-17 2018-07-23 Pfizer Metabolik ve ilişkili hastalıkların tedavisinde kullanılmaya yönelik diasilgliserol asiltransferaz 2 inhibitörleri.
SI3424534T1 (sl) 2014-04-15 2021-08-31 Vertex Pharmaceutical Incorporated Farmacevtski sestavki za zdravljenje bolezni, ki jih povzroča regulator transmembranske prevodnosti pri cistični fibrozi
WO2016022942A1 (en) 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺
MX370450B (es) 2014-10-07 2019-12-13 Vertex Pharma Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica.
EP3209960A1 (en) 2014-10-23 2017-08-30 Bend Research, Inc. Spray nozzle and process for making nanoparticles
CA2962719A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
JP6203702B2 (ja) * 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
UA123538C2 (uk) 2014-12-05 2021-04-21 Араґон Фармасьютікалз, Інк. Протиракові композиції
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
AU2016226279B2 (en) 2015-03-03 2021-11-11 Pharmacyclics Llc Pharmaceutical formulations of Bruton's tyrosine kinase inhibtor
US10596118B2 (en) 2015-03-10 2020-03-24 Shionogi, Inc. Solid dispersions
US11848037B2 (en) 2015-07-29 2023-12-19 National University Of Singapore Method of protecting a magnetic layer of a magnetic recording medium
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN105223326B (zh) * 2015-09-23 2017-01-18 天津中医药大学 一种中药口服速释制剂中活性成分的体外分类方法
KR20180067658A (ko) 2015-10-15 2018-06-20 아지오스 파마슈티컬스 아이엔씨. 악성 종양의 치료를 위한 조합물 요법
WO2017066566A1 (en) 2015-10-15 2017-04-20 Agios Pharmaceuticals, Inc Combination therapy for treating malignancies
WO2017083348A1 (en) 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US10961355B2 (en) 2016-05-25 2021-03-30 Nutrition & Biosciences Usa 1, Llc Aqueous solution of cellulose ether acetate
RU2018145364A (ru) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
WO2018037310A1 (en) 2016-08-20 2018-03-01 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
US10231966B2 (en) 2016-10-27 2019-03-19 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
WO2018089810A1 (en) * 2016-11-10 2018-05-17 Regents Of The University Of Minnesota Surfactants and methods for making same
WO2018142296A2 (en) * 2017-02-01 2018-08-09 Zion Azar Systems methods devices apparatuses circuits and computer executable code for production and topical application of a therapeutic substance
JP7219223B2 (ja) 2017-03-10 2023-02-07 ファイザー・インク ＬＲＲＫ２阻害剤としての新規のイミダゾ［４，５－ｃ］キノリン誘導体
CN111818911B (zh) * 2017-12-26 2022-11-18 广东东阳光药业有限公司 一种鲁拉西酮固体分散体及其制备方法
WO2019134971A1 (en) * 2018-01-04 2019-07-11 Sandoz Ag Encapsulated particles comprising a pharmaceutically active ingredient
US11708463B2 (en) 2018-04-06 2023-07-25 Capsugel Belgium Nv Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
MX2021002428A (es) 2018-08-31 2023-01-02 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
WO2020058869A1 (en) 2018-09-21 2020-03-26 Pfizer Inc. N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
PE20211546A1 (es) 2018-10-05 2021-08-16 Pfizer Inhibidores de pde4 que contienen boro
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS
JP2022506622A (ja) * 2018-11-06 2022-01-17 ベイジン・イノケア・ファーマ・テク・カンパニー・リミテッド ６－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）ニコチンアミドを含有する非晶質固体分散体
EA202191371A1 (ru) * 2018-12-14 2021-12-27 Фуджифилм Корпорэйшн Фармацевтическая композиция и способ ее получения
TW202104228A (zh) 2019-04-11 2021-02-01 美商必治妥美雅史谷比公司 用於達到治療血漿濃度之增加效能的非晶形固體及經溶解調配物
JP2022529930A (ja) 2019-04-19 2022-06-27 ファイザー・インク Ｐａｈを処置するための抗増殖薬
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
EP3972596A1 (en) 2019-05-20 2022-03-30 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CA3141534A1 (en) 2019-05-23 2020-11-26 Helm Ag Nanoparticles comprising enzalutamide
US20220363673A1 (en) 2019-06-28 2022-11-17 Pfizer Inc. 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
CN114269328A (zh) 2019-08-15 2022-04-01 比利时胶囊公司 作为喷雾的固体分散体的加工助剂的氨
EP4023212A4 (en) * 2019-08-28 2023-08-30 Shenzhen Chipscreen Biosciences Co., Ltd. PHARMACEUTICAL COMPOSITION OF CHIDAMIDE, METHOD OF PREPARATION AND APPLICATION RELATED
JP2022548687A (ja) * 2019-09-18 2022-11-21 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害薬の剤形
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
BR112022011838A2 (pt) 2019-12-20 2022-08-30 Pfizer Derivados de benzimidazol
CN111184692B (zh) * 2020-02-14 2021-10-26 南京大渊医美生物技术有限公司 一种白藜芦醇的制剂及其制备方法
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
CN115515670A (zh) * 2020-03-19 2022-12-23 昂萨公司 经由注入的结晶和多孔固体交付气相抗微生物剂
BR112022024527A2 (pt) 2020-06-09 2022-12-27 Pfizer Compostos de espiro como antagonistas do receptor de melanocortina 4 e usos dos mesmos
CN111973596B (zh) * 2020-06-15 2022-02-15 深圳市泰力生物医药有限公司 具有改良溶出性质的抗肺纤维化组合物
TWI782599B (zh) 2020-07-02 2022-11-01 美商輝瑞股份有限公司 胺基嘧啶基衍生物
WO2022130175A1 (en) 2020-12-15 2022-06-23 Pfizer Inc. Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease
CA3205020A1 (en) 2020-12-15 2022-06-23 Pfizer Inc. Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease
EP4334300A1 (en) 2021-05-07 2024-03-13 GB005, Inc. Crystalline forms of n-{3-[(1s)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide and related products and methods
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
TW202337429A (zh) 2021-12-01 2023-10-01 美商輝瑞股份有限公司 支鏈酮酸脫氫酶激酶（ｂｃｋｄｋ）抑制劑及／或降解劑
WO2023105387A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127647A (en) 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS57176907A (en) 1981-04-23 1982-10-30 Yamanouchi Pharmaceut Co Ltd Readily absorbable solid pharmaceutical composition of as-56c
GB2132495B (en) 1982-12-16 1986-09-24 Cpc International Inc Spray drying
JPS61227524A (ja) 1985-03-30 1986-10-09 Tooa Eiyoo Kk プラゾシン製剤及びその製法
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
JP2528706B2 (ja) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
JPH0215027A (ja) 1988-07-01 1990-01-18 Takada Seiyaku Kk 新規なプロブコール固形製剤
ATE128959T1 (de) 1989-01-24 1995-10-15 Spi Polyols Inc Kryoschützende kristalline sorbitolkügelchen.
JPH0374396A (ja) 1989-08-16 1991-03-28 Mercian Corp 抗菌性組成物
US5013557A (en) 1989-10-03 1991-05-07 Warner-Lambert Company Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
EP0421582A1 (en) 1989-10-03 1991-04-10 Warner-Lambert Company Chewable spray dried spheroidal microcapsules and polymer coated microcapsules and method for preparing same
EP0421581A1 (en) 1989-10-03 1991-04-10 Warner-Lambert Company Chewable spray dried spheroidal microcapsules and wax coated microcapsules and methods for preparing same
ATE159426T1 (de) * 1991-04-16 1997-11-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer festen dispersion
TW209174B (pt) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
JP3717925B2 (ja) 1992-09-29 2005-11-16 ネクター セラピューティクス 副甲状腺ホルモンの活性フラグメントの肺導入
ATE223704T1 (de) * 1992-10-16 2002-09-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
JP3469926B2 (ja) 1993-11-04 2003-11-25 太田製薬株式会社 大腸内放出型医薬製剤用粒状物
WO1995024183A1 (en) 1994-03-07 1995-09-14 Inhale Therapeutic Systems Methods and compositions for pulmonary delivery of insulin
CN1093758C (zh) 1994-12-19 2002-11-06 第一制药株式会社 缓释粒状制剂及其制备方法
AU4314196A (en) 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
AU5794196A (en) * 1995-06-01 1996-12-18 G.D. Searle & Co. Stabilized solid dispersions of misoprostol
EP0784974B1 (en) 1995-07-26 2003-05-21 Kyowa Hakko Kogyo Co., Ltd. preparation of xanthine derivatives in a solid dispersion
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
JPH11514986A (ja) 1995-09-21 1999-12-21 ノバルティス アクチエンゲゼルシャフト 光力学的療法におけるナノ粒子
WO1997034610A1 (en) 1996-03-18 1997-09-25 Nissan Chemical Industries, Ltd. Process for producing efonidipine hydrochloride preparations
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
DK0910412T3 (da) 1996-07-01 2003-08-11 Univ Utrecht Hydrolyserbare hydrogeler til kontrolleret frigørelse
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6395302B1 (en) 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
EP1745774A3 (en) 1997-08-11 2007-04-11 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
DE60039377D1 (de) 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
GB9927011D0 (en) 1999-11-16 2000-01-12 Advanced Phytonics Ltd Method for the production of particles
CA2395129C (en) 1999-12-20 2008-12-16 Nicholas J. Kerkhof Process for producing nanometer particles by fluid bed spray-drying
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US6800297B2 (en) 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
JP2006140084A (ja) * 2004-11-15 2006-06-01 Koito Mfg Co Ltd 車両用灯具

Also Published As

Publication number Publication date
CY1107726T1 (el) 2013-04-18
JP2984661B2 (ja) 1999-11-29
ES2287971T3 (es) 2007-12-16
US8263128B2 (en) 2012-09-11
US8337899B2 (en) 2012-12-25
US20120292797A1 (en) 2012-11-22
CN101450212A (zh) 2009-06-10
IL125627A0 (en) 1999-04-11
DE69837903T2 (de) 2008-02-14
US8257741B2 (en) 2012-09-04
DE69837903D1 (de) 2007-07-26
DK0901786T3 (da) 2007-10-08
US20150024054A1 (en) 2015-01-22
US8431159B2 (en) 2013-04-30
CN1981742A (zh) 2007-06-20
PT901786E (pt) 2007-08-07
EP0901786A3 (en) 2000-01-19
TWI230079B (en) 2005-04-01
US20120328679A1 (en) 2012-12-27
IL125627A (en) 2009-02-11
CA2245269C (en) 2003-01-28
CN1207896A (zh) 1999-02-17
EP0901786A2 (en) 1999-03-17
ATE364374T1 (de) 2007-07-15
US8367118B2 (en) 2013-02-05
US20130224301A1 (en) 2013-08-29
EP0901786B1 (en) 2007-06-13
JPH11116502A (ja) 1999-04-27
US20120288542A1 (en) 2012-11-15
CA2245269A1 (en) 1999-02-11
US20030219489A1 (en) 2003-11-27
US20020009494A1 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
BR9803144A (pt) Dispersões farmacêuticas sólidas com uma biodisponibilidade aumentada.
EP1745774A3 (en) Solid pharmaceutical dispersions with enhanced bioavailability
DE60004052D1 (de) Pharmazeutische zubereitungen auf der basis von levodopa, carbidopa und entacapone
PT1032555E (pt) Aminoacidos ciclicos e derivados uteis como agentes farmaceuticos
DE69812089D1 (de) Pharmazeutische omeprazol-formulierung
IS1950B (is) Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
IS5130A (is) Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
HK1024182A1 (en) Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
IS5172A (is) Leysnistýring á lyfjum í augnvökvahólfinu
NO20021689L (no) 5-leddede heterocykliske derivater, fremstilling derav og anvendelse som medikamenter
PT1007505E (pt) Certos acidos 5-alquil-2-arilamino-fenilaceticos e derivados
CY1106159T1 (el) Φαρμακευτικη συνθεση που πepιλαμβανει πενιχρα υδατοδιαλυτη σταυροσπορινη, επιφανειοδραστικη ουσια και υδατοδιαλυτο πολυμepες
DE59813619D1 (de) Ascorbinsäurederivate enthaltende kosmetische und pharmazeutische Zubereitungen
ATE243708T1 (de) Substituierte imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
ATE449786T1 (de) Imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
NO20006646D0 (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
NO982874D0 (no) Farmas°ytiske preparater med vitamin D-analoger
DE50003454D1 (de) Proteinenthaltende pharmazeutische zubereitung
BR9808060B1 (pt) composição farmacêutica, e, uso da lamivudina ou um seu derivado farmaceuticamente aceitável.
DE69800970T2 (de) Pyridinderivate und sie enthaltende pharmazeutische zubereitungen
DE69812260D1 (de) Chromenderivate und deren Salze und diese enthaltende pharmazeutische Zubereitungen
PT1183241E (pt) Derivados da espiroimidazolidina sua preparacao sua utilizacao e preparacoes farmaceuticas que os contem
DK1236726T3 (da) Triazaspiro[5.5]undecan-derivater og lægemidler indeholdende samme som den aktive bestanddel
FR2759608B1 (fr) Dispersions aqueuses atomisables et redispersables
TH51174A (th) สารประกอบชนิดใหม่

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA (ART. 8O E 13 DA LPI)

B12B Appeal against refusal [chapter 12.2 patent gazette]